UnitedHealth is back and lifting other health-care stocks with it, Jim Cramer says

UnitedHealth is back and lifting other health-care stocks with it, Jim Cramer says


Traders work at the post where UnitedHealth Group is traded on the floor of the New York Stock Exchange.

Brendan McDermid | Reuters

UnitedHealth Group‘s (UNH) quality quarterly results Friday are a good sign for the broader health-care landscape, CNBC’s Jim Cramer said.

The managed-care giant earned an adjusted $6.56 per share on revenues of $92.4 billion in the three months ended Sept. 30. Both figures topped Wall Street expectations.

Shares of UnitedHealth rose roughly 2% on Friday to around $535 each. In a largely stronger day for the market overall, the S&P 500 health-care sector climbed nearly 1%, with only energy and financials performing better. It’s worth noting that UNH is the highest-priced stock in the Dow — so big swings in these shares can really move the 30-stock average.

If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free.

UnitedHealth “is a key component in the health-care universe, and … there will be a plethora of stocks that will trade well off this,” Cramer said on “Squawk on the Street.” Humana (HUM) is one of them — up nearly 2.5% on Friday. Cramer’s Charitable Trust, the portfolio used by the CNBC Investing Club, owns Humana shares.

Friday marked the second time UnitedHealth has reported quarterly results since it warned in June about elevated medical costs amid an uptick in procedures from seniors.

The company’s past comments had major ripple effects for health-care stocks, dragging down fellow insurers — such as Humana — while boosting shares of many medical device makers.

UnitedHealth’s better-than-expected second-quarter results in July helped soothe investor angst, and Cramer suggested Friday’s report offered additional assurance on medical cost trends. “UNH is back,” he added.

Including Friday’s gains, UNH shares turned slightly positive year to date.

Here’s a full list of the stocks in Jim’s Charitable Trust, the portfolio used by the CNBC Investing Club.



Source

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More
Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More